Marcin Skrzypski Amelia Szymanowska-Narloch Rafał Dziadziuszko
10.5114/wo.2017.70116
Contemp Oncol (Pozn)
2017;21(3):254-258.
tki inhibitors chemotherapy lung cancer osimertinib
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/29180936/
Case Reports
PMC5701587
29180936
Osimertinib - effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
2017